Table 2 Baseline characteristics of study participants. Data include the mean (±SD) or the number of persons (%)
|  | HOM group (n = 1543) | CON group (n = 981) |
|---|---|---|
Age (years) | 43.1 (±13.6) | 43.0 (±12.9) |
Women | 1208 (78.3) | 773 (78.8) |
Education, A level or similar | 965 (62.5) | 542 (55.2) |
Utilization of complementary medicine 12 months prior to baseline | 955 (61.9) | 119 (12.1) |
Per-protocol initial anamnesis in HOM group | 496 (32.1) | N/A |
State of residence (n (%)) | ||
 Abroad | 2 (0.1) | 0 (0) |
 Baden-Wuerttemberg | 185 (12) | 105 (10.7) |
 Bavaria | 206 (13.4) | 109 (11.1) |
 Berlin | 188 (12.2) | 59 (6.0) |
 Brandenburg | 40 (2.6) | 33 (3.4) |
 Bremen | 14 (0.9) | 10 (1.0) |
 Hamburg | 103 (6.7) | 56 (5.7) |
 Hesse | 118 (7.6) | 106 (10.8) |
 Mecklenburg-Western Pomerania | 24 (1.6) | 14 (1.4) |
 Lower Saxony | 123 (8.0) | 102 (10.4) |
 North-Rhine Westphalia | 300 (19.4) | 224 (22.8) |
 Rhineland-Palatinate | 87 (5.6) | 49 (5.0) |
 Saarland | 7 (0.5) | 7 (0.7) |
 Saxony | 22 (1.4) | 32 (3.3) |
 Saxony-Anhalt | 18 (1.2) | 13 (1.3) |
 Schleswig-Holstein | 90 (5.8) | 49 (5.0) |
 Thuringia | 16 (1.0) | 13 (1.3) |
Diagnosis and specific measures | ||
 Migraine/headache (G43.9/ R51) | 422 (27.3) | 266 (27.1) |
 Days with headache (last 4 weeks) | 7.2 (±6.1) | 6.2 (±5.6) |
 Utility valuea | 0.683 (±0.118) | 0.711 (±0.125) |
 Total costs previous 12 months in € (insurer perspective) | 1080.82 (±1064.27) | 1138.07 (±938.70) |
 Total costs previous 12 months in € (societal perspective) | 4399.99 (±8472.08) | 4476.86 (±7713.43) |
 Allergic rhinitis (J30.1) | 317 (20.5) | 188 (19.2) |
 RQLQ(S) score | 2.5 (±1.3) | 1.8 (±1.3) |
 AdolRQLQ score | 2.0 (±1.0) | 2.1 (±1.1) |
 Utility valuea | 0.727 (±0.124) | 0.788 (±0.118) |
 Total costs previous 12 months in € (insurer perspective) | 912.31 (±872.55) | 973.18 (±726.53) |
 Total costs previous 12 months in € (societal perspective) | 2716.87 (±5866.87) | 2867.22 (±5675.07) |
 Asthma (J45.9) | 123 (8.0) | 81 (8.3) |
 AQLQ(S) score | 5.1 (±0.9) | 5.5 (±1.1) |
 PAQLQ score | 4.3 (±1.1) | 5.8 (±0.8) |
 Utility valuea | 0.750 (±0.123) | 0.788 (±0.126) |
 Total costs previous 12 months in € (insurer perspective) | 1233.89 (±1226.28) | 1182.97 (±1071.87) |
 Total costs previous 12 months in € (societal perspective) | 3913.54 (±7459.30) | 3191.32 (±5544.62) |
 Atopic dermatitis (L20) | 229 (14.8) | 105 (10.7) |
 DLQI score | 8.9 (±6.1) | 6.1 (±5.4) |
 CDLQI score | 6.6 (±4.3) | 2.8 (±2.9) |
 Utility valuea | 0.743 (±0.128) | 0.788 (±0.119) |
 Total costs previous 12 months in € (insurer perspective) | 929.83 (±874.23) | 834.08 (±805.37) |
 Total costs previous 12 months in € (societal perspective) | 3150.44 (±7876.47) | 2644.33 (±3251.03) |
 Depression (F32.9) | 452 (29.3) | 341 (34.8) |
 BDI-II Score | 23.3 (±10.0) | 20.3 (±11.3) |
 Utility valuea | 0.621 (±0.103) | 0.666 (±0.123) |
 Total costs previous 12 months in € (insurer perspective) | 1666.76 (±1821.34) | 1737.11 (±1091.65) |
 Total costs previous 12 months in € (societal perspective) | 10,679.85 (±17,270.82) | 7634.41 (±11,252.44) |